Beginners’ Portfolio: News From Aviva plc, Persimmon plc And GlaxoSmithKline plc

The latest from Aviva plc (LON: AV) and Persimmon plc (LON: PSN), and we check on GlaxoSmithKline plc (LON: GSK)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article is the latest in a series that aims to help novice investors with the stock market. To enjoy past articles in the series, please visit our full archive.

The Beginners’ Portfolio is a virtual portfolio, which is run as if based on real money with all costs, spreads and dividends accounted for.

A few of our Beginners’ Portfolio shares have been in the news recently, but before I tale a look at them here’s a quick valuation update:

Company Shares Buy price Total cost Bid price Proceeds Gain/loss % change
Vodafone 289 168.5p £499.51 188.3p £534.19 £34.68 6.9%
Tesco 159 305.5p £498.23 370.4p £578.94 £80.71 16.2%
GlaxoSmithKline 34 1,440.5p £502.22 1,668p £557.12 £54.90 10.9%
Persimmon 79 617.9p £500.55 1,110p £866.90 £366.35 73.2%
Blinkx 1,319 36.9p £499.68 133.5p £1,750.87 £1,251.19 250.4%
BP 112 434.5p £499.01 451.8p £496.02 -£2.99 -0.6%
Rio Tinto 16 3,048.4p £500.18 2,946p £461.36 -£38.82 -7.8%
BAE Systems 146 332.3p £497.59 440.2p £632.69 £135.10 27.2%
Apple 2 $458.4 £605.98 $487.5 £611.53 £5.55 0.9%
Aviva 146 321.4p £499.71 391.5p £561.59 £63.88 12.8%
Dividends         £265.55 £265.55  
Total     £5,100.66   £7,316.75 £2,216.09 43.4%

With a 43.4% gain since we started, including dividends and all costs, we’re not doing too badly. I had a pleasant surprise checking these figures when I realised I’d forgotten to include the 75p-per-share special dividend paid by Persimmon (LSE: PSN) in June (the ex-dividend date was in April), and that gave us another £59.25 to add to the pot!

Aviva

avivaOur favourite insurer Aviva (LSE: AV) (NYSE: AV.US) released first-half results on 8 August, and we haven’t had a look at them until today. (There’s a beginners’ lesson there — unless there’s anything unexpected on the day, as long-term investors we can take our time getting round to it.)

Things looked pretty good, with chief executive Mark Wilson saying “We have achieved profit after tax of £776 million, in contrast to the £624 million loss last year. Cash flows to the Group have increased by 30% to £573 million“. New business climbed 17% too, and the firm slashed its operating expenses by 9% to £1.5bn, though Mr Wilson was quick to point out that “tackling our legacy issues will take time“. (And that’s another note for beginners — I like it when a CEO is up-front about things like that, in this case right at the start of the report.)

There is clearly still work to be done, but I’m satisfied with the company’s turnaround progress so far and I’m happy to keep taking 4% dividends. I also remain convinced that the sell-off earlier this year was overdone and that Aviva shares are still cheap.

Persimmon

Persimmon also gave us first-half results, on 20 August, and they looked pretty good to me. Legal completions were up 7% to 5,022, revenue was up 12% to £899.9m, and underlying pre-tax profit soared by 40% to £135.3m. Net cash inflow is rising, the firm is investing in new land, and forward sales are up 21%. The government’s Help to Buy scheme is certainly helping Persimmon to sell, and all in all I’d say we’re looking at the pretty-much-inevitable recovery in the business.

As for that special dividend of 75p per share, we weren’t going to get any more until a 95p payment in 2015. But Persimmon has decided to accelerate its “capital return plan” and now intends to pay 10p per share of it in June 2014. There’ll be no complaints from me about that — the real attraction to me is long-term regular dividends, but a shorter-term boost to income is always welcome.

GlaxoSmithKline

GlaxoSmithKlineWhen we added GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) back in June 2012, one of the big fears for the business was the expiry of patents and the resulting increased competition from generic drugs. But I thought Glaxo was more in tune with the need to expand into newer biotechnology and novel treatments.

News on 13 August gave me some confidence in that feeling, with the drug Tivicay (with the generic name dolutegravir) receiving approval from the US Food and Drug Administration (FDA) for the treatment of HIV-1. Tivicay has been developed by ViiV Healthcare, which is 76% owned by Glaxo after the firm pooled its HIV resources with Pfizer. This is potentially very big news, and I think Glaxo is handling its transition well.

Finally, my idea of the kind of shares that should make up the core of a beginner’s portfolio is the same as my choice for an ISA, or a retirement portfolio — or in fact, any portfolio. I’d start with good strong companies that should stand the test of time and potentially reward you for decades.

Not surprisingly, the Fool’s top analysts think similarly, and they have put together a special report detailing five blue-chip shares that I think would be ideal for anyone at the start of their investing career.

But it will only be available for a limited period, so click here to get your hands on these great ideas that could start you on the road to long-term riches.

> Alan does not own any shares mentioned in this article. The Motley Fool owns shares in Tesco and has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

Should I buy more Rolls-Royce shares near 500p?

This investor is wondering whether to buy more Rolls-Royce shares this summer or to just stick with those he already…

Read more »

Investing Articles

After its big fall, is the National Grid share price dirt cheap now?

The National Grid share price fell sharply in reponse to new rights issue plans. But is it an even better…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Starting in June, I’d invest £1,000 a month to aim for a £102,000 second income in retirement

This author highlights a less well-known FTSE 100 stock that could help his portfolio generate a very big second income…

Read more »

Investing Articles

Down 47% in 5 years, is the IAG share price due a bounce?

Many companies in the travel sector have seen fierce rallies since 2020. But with the IAG share price still down…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Despite its drop, I reckon this is one of the best FTSE 100 stocks to buy and hold!

The FTSE 100 has been climbing in 2024 but this favourite of our writer's has been falling. Despite this, she’s…

Read more »

Investing Articles

AI stocks vs EV shares; which is the best sector for me to invest in?

Jon Smith considers the recent rally in AI stocks and weighs up whether to allocate more money there versus EV…

Read more »

A graph made of neon tubes in a room
Investing Articles

Do Greggs shares have even more growth ahead?

Greggs shares have seen some solid growth in the last few months, as the economy shows positive signs. But is…

Read more »

Investing For Beginners

How I’d aim to grow my Stocks & Shares ISA from £20k to £1m

Jon Smith explains how diversification and focusing on sectors for the future can help grow his Stocks and Shares ISA.

Read more »